Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

  • This share is currently suspended. It was suspended at a price of 43.10
  • There is currently no data for LABS

Form 8.3

29 Jan 2026 15:00

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

 

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

Life Science REIT plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

28 January 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

 

British Land Company plc, The

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

1p ordinary

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

(2) Cash-settled derivatives:

 

6,415,992

 

1.83%

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

TOTAL:

 

6,415,992

 

1.83%

 

 

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

 

Purchase/sale

 

Number of securities

 

Price per unit

 

 

 

 

 

 

(b) Cash-settled derivative transactions

Class of relevant security

 

Product description

e.g. CFD

 

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 

Number of reference securities

 

Price per unit

1p ordinary

 

CFD

 

Opening a long position

 

2,250,000

 

42.31 GBp

1p ordinary

 

CFD

 

Increasing a long position

 

4,138,907

 

42.2758 GBp

1p ordinary

 

CFD

 

Increasing a long position

 

27,085

 

42.5 GBp

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

 

Product description e.g. call option

 

Writing, purchasing, selling, varying etc.

 

Number of securities to which option relates

 

Exercise price per unit

 

Type

e.g. American, European etc.

 

Expiry date

 

Option money paid/ received per unit

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

 

Product description

e.g. call option

 

Exercising/ exercised against

 

Number of securities

 

Exercise price per unit

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

 

Nature of dealing

e.g. subscription, conversion

 

Details

 

Price per unit (if applicable)

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

 

No

Date of disclosure:

 

29 January 2026

Contact name:

 

James Evans

Telephone number:

 

+44 20 3161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260129126501/en/

Copyright Business Wire 2026

Date   Source Headline
3rd Sep 20256:31 pmRNSForm 8.3 - Life Science REIT plc
3rd Sep 20254:26 pmRNSForm 8.3 - Life Science REIT plc
3rd Sep 20253:20 pmRNSForm 8.3 - Life Science REIT plc
3rd Sep 20252:03 pmRNSForm 8.3 - Life Science REIT plc
3rd Sep 20251:54 pmGNWForm 8.3 - Life Science REIT Plc
3rd Sep 202510:19 amRNSForm 8.5 (EPT/RI)
2nd Sep 20254:50 pmRNSForm 8.3 - Life Science REIT
2nd Sep 20253:20 pmRNSForm 8.3 - Life Science REIT plc
2nd Sep 202512:38 pmGNWForm 8.3 - Life Science REIT Plc
2nd Sep 202510:32 amRNSForm 8.5 (EPT/RI)
1st Sep 20253:20 pmRNSForm 8.3 - Life Science REIT plc
1st Sep 20252:40 pmGNWForm 8.3 - Life Science REIT Plc
1st Sep 202511:10 amRNSForm 8.3 - Life Science REIT plc
1st Sep 202510:46 amRNSForm 8.5 (EPT/RI)
29th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
29th Aug 202511:50 amRNSForm 8.3 - Life Science REIT plc
29th Aug 202510:49 amRNSForm 8.5 (EPT/RI)
29th Aug 202510:43 amRNSForm 8.3 - LIFE SCIENCE REIT PLC
28th Aug 20251:31 pmRNSForm 8.3 - Life Science REIT plc
28th Aug 20251:08 pmGNWForm 8.3 - Life Science REIT Plc
27th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
27th Aug 202511:44 amGNWForm 8.3 - Life Science REIT Plc
27th Aug 202510:41 amRNSForm 8.3 - Life Science REIT plc
26th Aug 202511:47 amGNWForm 8.3 - Life Science REIT Plc
22nd Aug 20252:05 pmGNWForm 8.3 - Life Science REIT Plc
22nd Aug 202511:16 amRNSForm 8.3 - Life Science REIT plc
22nd Aug 20259:48 amRNSForm 8.5 (EPT/RI)
21st Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
21st Aug 20251:59 pmGNWForm 8.3 - Life Science REIT Plc
21st Aug 202510:50 amRNSForm 8.5 (EPT/RI)
21st Aug 202510:16 amRNSForm 8.3 - Life Science REIT PLC
20th Aug 20253:21 pmGNWForm 8.3 - Life Science REIT Plc
20th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
20th Aug 202510:34 amRNSForm 8.5 (EPT/RI)
19th Aug 20254:40 pmRNSForm 8.3 - Life Science REIT
19th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
18th Aug 20251:44 pmGNWForm 8.3 - Life Science REIT Plc
18th Aug 202510:26 amRNSForm 8.5 (EPT/RI)
15th Aug 20254:27 pmRNSForm 8.3 - Life Science
15th Aug 20252:55 pmGNWForm 8.3 - Life Science REIT Plc
15th Aug 20259:53 amRNSForm 8.5 (EPT/RI)
14th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
14th Aug 20252:03 pmGNWForm 8.3 - Life Science REIT Plc
14th Aug 202510:23 amRNSForm 8.5 (EPT/RI)
13th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
13th Aug 202512:02 pmGNWForm 8.3 - Life Science REIT Plc
13th Aug 202510:52 amRNSForm 8.3 - Life Science REIT plc
13th Aug 202510:30 amRNSForm 8.5 (EPT/RI)
12th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
12th Aug 202510:00 amRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.